ArticleAnnals of medicine and surgery (2012)2026
The risk of developing acute myeloid leukemia in patients with Ewing sarcoma and trend analysis: a SEER-based study.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ewing sarcoma (ES) is a neoplasm of neuroectodermal origin arising from bone or soft tissue. The annual incidence of ES is 2.93 per 1, 000, 000. Acute myeloid leukemia (AML) is one of the most described second malignancies as a complication of primary cancer therapy. There is a lack of recent studies elaborating on the incidence rates of such complications. So, the aim was to quantify the risk of developing AML as a second primary malignancy (SPM) in ES patients and to provide an updated evidence to the literature. Methods: We extracted the data from the Surveillance, Epidemiology and End Results (SEER) program statistical analysis software package (SEER*Stat, version 8.4.1.2). We used an MP-SIR session to identify patients diagnosed with AML as an SPM after ES as a first primary malignancy between 2000 and 2020. We assessed the SIR as Observed/Expected(O/E) and Excess Absolute Risk (EAR) per 10, 000 with a 95% confidence interval (CI) and statistical significance at 0.05. Results: A total of 2631 patients with ES were recorded in the SEER database, with a median follow-up of 120 + months. Patients with ES had an increased risk of developing AML with an O/E of 145.98 ( Conclusion: Patients treated for a primary ES have a significant risk of developing AML, among other second primary malignancies. Thus, we recommend screening for AML from 2 to 11 months after the diagnosis of ES for early detection and better management outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.